Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


DIREVO announces validation of bestMab
Powerful new approach for the optimization of therapeutic antibodies generates optiMIRA


Cologne (Germany), May 6, 2008 – DIREVO Biotech AG announced today that it has validated its “bestMab™” platform through the generation of an optimized version of the anti-inflammatory antibody, Adalimumab (Humira®), with unprecedentedly strong binding properties. optiMIRA™ shows 300-times tighter antigen binding than Humira®, and more than 15-fold tighter binding than the previously most advanced optimized Humira® derivative, which was generated using display technology. The results of this study were presented on May 1st, 2008 at the Fourth Annual Protein Engineering Summit (PEGS) conference in Boston, USA. The presentation can be viewed at http://www.direvo.com/bestMab/PEGS

The bestMab™ technology comprises a novel, integrated, and highly effective platform for improving the properties of therapeutic antibodies. The platform achieves this without making use of display technologies, and is applicable to all types of antibodies from any origin, including antibodies derived from either immunized mice or recombinant antibody libraries. Significantly, the bestMab™ process identifies virtually all mutations that can improve the antibody of interest. Using bestMab™, DIREVO optimized the marketed antibody, Humira®, to generate optiMIRA™, which binds to TNFa with an exceptional binding strength (femtomolar affinity).

”This is a major technical and commercial breakthrough in antibody engineering that has the potential to significantly enhance antibody drug development,” said Dr. Thomas von Rüden, CEO of DIREVO. “I am very proud of our interdisciplinary team of scientists and technicians who have made this important contribution to a key area of antibody R&D.”

DIREVO will use bestMab™ as a proprietary cornerstone of its therapeutic antibody platform. Based on bestMab™, DIREVO will generate superior 2nd generation antibodies and improve success rates of antibodies in development, both for internal proprietary programs and through partnerships with the pharmaceutical and biopharmaceutical industries.

- end -

More about bestMab™

The bestMab™ technology relies on DIREVO’s leading protein engineering platform, which is characterized by highly predictive screens of high throughput. These screens allow effective antibody engineering using the more informative “clonal” and “solution-based” assays, as opposed to the more traditional use of display technology. Another distinctive feature of the bestMab™ approach is its more comprehensive and efficient approach to the engineering of antibody properties. This respectively translates into the more complete generation of IP covering all changes that can improve a given antibody, as well as into antibodies that reach product qualification goals with fewer mutations.

Using the bestMab™ approach, highly valuable synergistic interactions can be identified by the extensive generation and testing of a large number of combinatorial antibody libraries. In each library, two antibody binding region (complementarity determining region, or CDR) positions are paired for simultaneous co-optimization. This approach is then extended to every residue in all six CDRs, to yield a large number of such “paired-saturation” libraries. Extensive exploitation of such an approach is only possible using screens of very high throughput. For example, in the first screening round, well over 100,000 variants were individually and quantitatively screened to compare their properties on a proprietary platform that allows over 50,000 variants to be screened per day.

Elements of the bestMab™ approach thus ensure that:

(i) virtually every amino acid substitution that can improve a given antibody is identified,

(ii) synergistic interactions that are typically missed in other approaches are identified,

(iii) the number of mutations is minimized because the antibody receives the optimal combination of amino acid exchanges,

(iv) so<


Publisher Contact Information:

Direvo
+ 49 221 8887-121
info@DIREVO.com

Company profile of Direvo (acquired by Bayer HealthCare)
Past press releases of Direvo (acquired by Bayer HealthCare).

Data


25,747
Tech investments
From our Online Data Service
16,670
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 24€4.1MArtificial Intelligence
May 24€0.6MArtificial Intelligence
May 24€3.0MMedical devices
May 24€9.0MRobotics
May 23N/AConsumer applications
May 23€4.5MInternet services
May 23€12.0MOther Biotechnology & Healthcare

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.